Nintedanib in idiopathic and secondary pleuroparenchymal fibroelastosis

BACKGROUND: Pleuroparenchymal fibroelastosis (PPFE) has a variable disease course with dismal prognosis in the majority of patients with no validated drug therapy. This study is to evaluate the effect of nintedanib in patients with idiopathic and secondary PPFE. Patients admitted to a tertiary care...

Descripción completa

Detalles Bibliográficos
Autores principales: Nasser, Mouhamad, Si-Mohamed, Salim, Turquier, Ségolène, Traclet, Julie, Ahmad, Kaïs, Philit, François, Bonniaud, Philippe, Chalabreysse, Lara, Thivolet-Béjui, Françoise, Cottin, Vincent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8501734/
https://www.ncbi.nlm.nih.gov/pubmed/34627338
http://dx.doi.org/10.1186/s13023-021-02043-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8501734/
https://www.ncbi.nlm.nih.gov/pubmed/34627338
http://dx.doi.org/10.1186/s13023-021-02043-5

Ejemplares similares